Salivary secretory leukocyte protease inhibitor levels in patients with stage 3 grade C periodontitis: a comparative cross-sectional study

Abstract

Secretory leukocyte protease inhibitor (SLPI) is an anti-protease that protects mucosal tissue integrity owing to its anti-microbial and immunomodulatory properties. This study aimed to investigate SLPI levels in periodontal diseases, and analyze the potential correlation with clinical periodontal parameters. Whole saliva samples were obtained from healthy (n = 24), gingivitis (n = 24) and patients with stage 3 grade C periodontitis (n = 24). SLPI was measured by ELISA and normalized by total protein. Receiver operating characteristics (ROC) curve was used for estimating the area under the curve (AUC). The normalized SLPI levels were significantly reduced in periodontitis compared with gingivitis (4.84-fold) or health (1.83-fold) and negatively correlated with periodontal parameters. The ROC curves showed a good predictor value of the SLPI for differentiation of periodontitis versus health or gingivitis (AUC ≥ 0.80). This study demonstrates that the levels of SLPI are high in periodontal health, further elevated in gingivitis, but eventually decreased in severe periodontitis beyond the former two states. This observation may have broader implications in the context of inflammatory diseases affecting the oral mucosa, as it shows that the bacterial burden is disturbing the homeostatic balances of anti-microbial and anti-protease factors in the oral cavity.

Figure 1

ROC curve for normalized salivary SLPI levels to identify periodontitis versus periodontal health. AUC: 0.81 with 83% sensitivity and 75% specificity (95% CI for the AUC: 0.68–0.93). ROC receiver operating characteristic, SLPI secretory leukocyte protease inhibitor, CI confidence interval, AUC area under the curve, ng nanogram, mg milligram.

Figure 2

ROC curve for normalized salivary SLPI levels to identify periodontitis versus gingivitis. AUC: 0.82 with 100% sensitivity and 75% specificity (95% CI for the AUC: 0.68–0.96). ROC receiver operating characteristic, SLPI secretory leukocyte protease inhibitor, CI confidence interval, AUC area under the curve, ng nanogram, mg milligram.